EQ302 / Equillium - LARVOL DELTA

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights (Businesswire) - P2 | N=36 | NCT05589610 | Sponsor: Equillium | "Announced positive topline data from Phase 2 study of EQ101 in alopecia areata subjects, including 29% of completed subjects with moderate to severe disease achieving SALT (Severity Alopecia Tool) ≤ 20....Anticipated Upcoming Milestones: EQ101: Transition to subcutaneous delivery and initiate Phase 2 dose optimization study in alopecia areata – 2025. EQ302: Initiate Phase 1 study – 2H 2025....Revenue for the second quarter of 2024 was $13.9 million, compared to $9.1 million during the same period in 2023. Revenue in the second quarters of 2024 and 2023 consisted entirely of itolizumab development funding and amortization of the upfront payment resulting from the Asset Purchase Agreement with Ono.

Commercial • New P2 trial • P2 data • Acute Graft versus Host Disease • Alopecia • Immunology

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium (Businesswire) - "Equillium Inc...announced a presentation at the 18th Annual Peptide Therapeutics Symposium highlighting EQ302, a second generation orally deliverable multi-cytokine inhibitor in development to target IL-15 and IL-21....The presentation outlines the origins of EQ302 from its parent peptide, EQ102, which was originally modeled from the D-helix of the IL-2 family of cytokines and binds directly to CD132 to inhibit the signaling of IL-15 and IL-21....EQ302 delivered to mice via oral gavage can inhibit IL-15-induced IFNγ transcription locally in the GI tract indicating potential utility for Celiac Disease and inflammatory bowel disease.​"

Preclinical • Celiac Disease • Inflammatory Bowel Disease